Diagnosis

Pelvic inflammatory disease

An inflammation of the upper genital tract in females tha can affect:

  • Uterus

  • Fallopian tubes (salpingitis)

  • Ovaries

Also known as: Acute salpingitis

Etiology

Cause [ypn]

Pathophysiology [7m5][ypn]

  1. Primary salpingitis: Disruption of the cervical barrier --> Ascending spread from the non-sterile lower genital tract (vagina) to sterile organs (uterus, tubes, ovaries)

    1. Veneral (85%): Sexually transmitted microorganisms

    2. Iatrogenic: Diagnostic or therapeutic procedures or by IUD insertions

    3. Endogenous agents: Spread from the endogenous vaginal or perianal flora

  2. Secondary salpingitis: Infection of the Fallopian tubes caused by direct spread from nearby pelvic organs, most often the appendix

  3. Infection of the upper female genital tract --> inflammatory damage:

    • Scarring, adhesions, stricture in the fallopian tubes --> risk of infertility, ectopic pregnancy and chronic pelvic pain

Risk factors

Complications [cir][ypn]

Epidemiology

Incidence per 100.000 [iu2][msk][tfg][o6t][7m5][nr6][gbo]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Amenorrhea, Cervical motion tenderness, Dysuria, Fever, Menorrhagia, Metrorrhagia, Nausea, Vaginal discharge, Vomiting

Clinical findings

Elevated CRP, Elevated Sedimentation Rate, Leukocytosis

Anamneses

None listed.

Localized findings

Pain
Radiates
Regio hypogastrica
Onset
Subacute (hours)Gradual (days)
Pattern
Constant
Provoked by
ActivityCoitusUrination
Quality
AchingCrampingDull
Severity
Mild (1-3)Moderate (4-7)
Swelling
Radiates
Regio hypogastrica
Onset
Gradual (days)
Pattern
Constant

Approach

Suspicion of tubal infection: [7m5]

  1. Signs of genital infection

  2. Low abdominal pain

  3. Pelvic tenderness

In addition; one or more of:

  1. Erythrocyte sedimentation rate > 15 mm/hr

  2. Rectal temperature >38.0” C

  3. Palpable adnexal mass

Treatment

  1. Antibiotics: [ypn][cbr][w1v]

    • Cefotetan 2 g x 2 IV + doxycycline 100 mg x 2 or

    • Cefoxitin 2 g x 4 IV + doxycycline 100 mg x 2 or

    • Clindamycin 900 mg x 3 IV + gentamicin 3 to 5 mg/kg IV x 1

    • Metronidazole 500 mg x 2 for 14 days should be added if trichomonas or recent vaginal instrumentation

  2. Supportive care:

    • Fluid management

    • Antiemetics

    • Analgesics

  3. Surgery: Drainage of tubo-ovarian abscess

Differential diagnoses

Appendicitis, Cervicitis, Diverticulitis, Endometriosis, Interstitial cystitis, Irritable bowel syndrome, Ovarian abscess, Ovarian cancer, Ovarian torsion, Pyelonephritis, Ruptured ectopic pregnancy, Ruptured ovarian cyst, Urinary tract infection


References

[1] Jenkins SM, Vadakekut ES. Pelvic Inflammatory Disease. [Updated 2025 Jun 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499959/

[2] Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 2):880-92.

[3] Weström L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992 Jul-Aug;19(4):185-92.

[4] Davis GS, Horner PJ, Price MJ, Mitchell HD, Soldan K. What Do Diagnoses of Pelvic Inflammatory Disease in Specialist Sexual Health Services in England Tell Us About Chlamydia Control? J Infect Dis. 2021 Aug 16;224(12 Suppl 2):S113-S120.

[5] Public Health England. Rates of Pelvic Inflammatory Disease (PID) in England (2000-2013). Health Protection Report. Volume 9 Number 22. Advanced Access report published on: 23 June 2015.

[6] Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial BMJ 2010; 340 :c1642.

[7] Fenton KA, Korovessis C, Johnson AM, McCadden A, McManus S, Wellings K, Mercer CH, Carder C, Copas AJ, Nanchahal K, Macdowall W, Ridgway G, Field J, Erens B. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet. 2001 Dec 1;358(9296):1851-4.

[8] Kreisel K, Torrone E, Bernstein K, Hong J, Gorwitz R. Prevalence of Pelvic Inflammatory Disease in Sexually Experienced Women of Reproductive Age - United States, 2013-2014. MMWR Morb Mortal Wkly Rep. 2017 Jan 27;66(3):80-83.

[9] Kreisel KM, Llata E, Haderxhanaj L, Pearson WS, Tao G, Wiesenfeld HC, Torrone EA. The Burden of and Trends in Pelvic Inflammatory Disease in the United States, 2006-2016. J Infect Dis. 2021 Aug 16;224(12 Suppl 2):S103-S112.

[10] Ness RB, Trautmann G, Richter HE, Randall H, Peipert JF, Nelson DB, Schubeck D, McNeeley SG, Trout W, Bass DC, Soper DE. Effectiveness of treatment strategies of some women with pelvic inflammatory disease: a randomized trial. Obstet Gynecol. 2005 Sep;106(3):573-80.

[11] http://emedicine.medscape.com/article/256448 (2014-01-02); [Medscape]

Scroll to top